| Randomized trial of safinamide add‐on to levodopa in Parkinson's disease with motor fluctuations R Borgohain, J Szász, P Stanzione, C Meshram, M Bhatt, D Chirilineau, ... Movement Disorders 29 (2), 229-237, 2014 | 324 | 2014 |
| Two‐year, randomized, controlled study of safinamide as add‐on to levodopa in mid to late Parkinson's disease R Borgohain, J Szasz, P Stanzione, C Meshram, MH Bhatt, D Chirilineau, ... Movement Disorders 29 (10), 1273-1280, 2014 | 270 | 2014 |
| Levodopa-carbidopa intestinal gel in advanced Parkinson's: final results of the GLORIA registry A Antonini, W Poewe, KR Chaudhuri, R Jech, B Pickut, Z Pirtošek, J Szasz, ... Parkinsonism & related disorders 45, 13-20, 2017 | 217 | 2017 |
| Factors influencing hemorrhagic transformation in ischemic stroke: a clinicopathological comparison L Kerenyi, L Kardos, J Szász, S Szatmári, D Bereczki, K Hegedüs, L Csiba European journal of neurology 13 (11), 1251-1255, 2006 | 126 | 2006 |
| Neuroinflammation and microglia/macrophage phenotype modulate the molecular background of post-stroke depression: A literature review EE Nagy, A Frigy, JA Szász, E Horváth Experimental and therapeutic medicine 20 (3), 2510-2523, 2020 | 58 | 2020 |
| The effect of levodopa–carbidopa intestinal gel infusion long-term therapy on motor complications in advanced Parkinson’s disease: a multicenter Romanian experience O Băjenaru, A Ene, BO Popescu, JA Szász, M Sabău, DF Mureşan, ... Journal of Neural Transmission 123, 407-414, 2016 | 51 | 2016 |
| Concomitant medication usage with levodopa‐carbidopa intestinal gel: results from the COSMOS study A Fasano, T Gurevich, R Jech, N Kovács, P Svenningsson, J Szász, ... Movement Disorders 36 (8), 1853-1862, 2021 | 40 | 2021 |
| Prestroke alcohol consumption and smoking are not associated with stroke severity, disability at discharge, and case fatality K Fekete, S Szatmári, I Szőcs, C Szekeres, J Szász, L Mihálka, ... Journal of Stroke and Cerebrovascular Diseases 23 (1), e31-e37, 2014 | 34 | 2014 |
| Profile of patients with advanced Parkinson’s disease suitable for device-aided therapies: restrospective data of a large cohort of Romanian patients JA Szász, VA Constantin, K Orbán-Kis, A Rácz, LA Bancu, D Georgescu, ... Neuropsychiatric Disease and Treatment, 3187-3195, 2019 | 29 | 2019 |
| Therapeutic strategies in the early stages of Parkinson’s disease: a cross-sectional evaluation of 15 years’ experience with a large cohort of Romanian patients JA Szász, K Orbán-Kis, VA Constantin, C Péter, I Bíró, I Mihály, K Szegedi, ... Neuropsychiatric Disease and Treatment, 831-838, 2019 | 24 | 2019 |
| Levodopa-carbidopa intestinal gel infusion therapy discontinuation: A ten-year retrospective analysis of 204 treated patients VA Constantin, JA Szász, K Orbán-Kis, EC Rosca, M Popovici, A Cornea, ... Neuropsychiatric Disease and Treatment, 1835-1844, 2020 | 23 | 2020 |
| The role of selective monoamine oxidase B inhibitors in the therapeutic strategy of Parkinson's disease in the neurology clinics of Tirgu Mures County Emergency Clinical Hospital JA Szász, V Constantin, PA Fazakas, E Blényesi, LG Grieb, A Balla, ... Orvosi Hetilap 158 (51), 2023-2028, 2017 | 19 | 2017 |
| Dopamine agonists in Parkinson's disease therapy-15 years of experience of the Neurological Clinics from Tîrgu Mureș. A cross-sectional study JA Szász, C Viorelia, I Mihály, I Biró, C Péter, K Orbán-Kis, S Szatmári Ideggyogyaszati Szemle 72 (5-6), 187-193, 2019 | 17 | 2019 |
| Characteristics of levodopa treatment in advanced Parkinson's disease in the experiences of the neurology clinics of Târgu Mureș, Romania JA Szász, S Szatmári, V Constantin, I Mihály, A Rácz, LC Domokos, ... Orvosi Hetilap 160 (17), 662-669, 2019 | 16 | 2019 |
| Characterizing Advanced Parkinson’s Disease: Romanian Subanalysis from the OBSERVE‐PD Study JA Szasz, DC Jianu, MA Simu, VA Constantin, AO Dulamea, K Onuk, ... Parkinson’s Disease 2021 (1), 6635618, 2021 | 15 | 2021 |
| Management challenges of severe, complex dyskinesia. Data from a large cohort of patients treated with levodopa-carbidopa intestinal gel for advanced Parkinson’s disease JA Szász, VA Constantin, K Orbán-Kis, LA Bancu, M Ciorba, I Mihály, ... Brain Sciences 11 (7), 826, 2021 | 13 | 2021 |
| The Mureş–Uzhgorod–Debrecen study: a comparison of hospital stroke services in Central‐Eastern Europe S Szatmári, I Pascu, L Mihálka, SV Mulesa, I Fekete, B Fülesdi, L Csiba, ... European Journal of Neurology 9 (3), 293-296, 2002 | 13 | 2002 |
| Levodopa–carbidopa–entacapone intestinal gel in advanced parkinson disease: a multicenter real-life experience JA Szász, AO Dulamea, VA Constantin, DF Mureşanu, LP Dumbravă, ... American Journal of Therapeutics, 10.1097, 2022 | 11 | 2022 |
| Long‐term safety and tolerability of lacosamide monotherapy in patients with epilepsy: Results from a multicenter, open‐label trial E Ben‐Menachem, J Dominguez, J Szász, C Beller, C Howerton, ... Epilepsia open 6 (3), 618-623, 2021 | 11 | 2021 |
| Motor and nonmotor symptoms in patients treated with 24-hour daily levodopa-carbidopa intestinal gel infusion: analysis of the COmedication Study assessing Mono-and cOmbination … N Kovács, J Szász, L Vela-Desojo, P Svenningsson, S Femia, JC Parra, ... Parkinsonism & Related Disorders 105, 139-144, 2022 | 10 | 2022 |
